Seyyar M., Kalem A., Sali M., Karabuğa B., Sahin T. K., Dişli A. K., ...Daha Fazla
CURRENT ONCOLOGY, cilt.33, sa.6, ss.1-20, 2026 (SCI-Expanded, Scopus)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
33
Sayı:
6
-
Basım Tarihi:
2026
-
Doi Numarası:
10.3390/curroncol33060365
-
Dergi Adı:
CURRENT ONCOLOGY
-
Derginin Tarandığı İndeksler:
Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Scopus, Science Citation Index Expanded (SCI-EXPANDED), CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
-
Sayfa Sayıları:
ss.1-20
-
Açık Arşiv Koleksiyonu:
AVESİS Açık Erişim Koleksiyonu
-
İstanbul Üniversitesi-Cerrahpaşa Adresli:
Evet
Özet
Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and prognostic factors in a multicenter retrospective Turkish cohort treated with a CDK4/6 inhibitor plus endocrine therapy (June 2020–September 2025). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier and Cox methods. Among 121 patients, 30 (24.8%) had BRCA1, 88 (72.7%) had BRCA2, and three (2.5%) had dual mutations; 66.9% received first-line therapy, with ribociclib in 69.4% and palbociclib in 29.8%. Objective response rate was 69.4% and the clinical benefit rate was 82.6%. Median PFS was 17.0 months and OS 47.0 months. PFS was numerically longer in BRCA1 than in BRCA2 carriers (25.0 vs. 14.0 months), although the difference was not statistically significant in the pairwise comparison (HR 1.50, 95% CI 0.88–2.56; log-rank p = 0.135); the dual BRCA1/2 subgroup (n = 3) had the poorest outcomes and was assessed descriptively. OS did not differ significantly between BRCA1 and BRCA2 carriers (57.0 vs. 49.0 months; log-rank p = 0.520). PFS did not differ between ribociclib and palbociclib (p = 0.192); OS favored ribociclib at borderline significance (p = 0.050), but this was not confirmed in Cox regression. In multivariable analysis, ECOG ≥ 1 (HR 1.85; p = 0.010) and fulvestrant-based therapy (HR 1.74; p = 0.041) predicted shorter PFS; fulvestrant also predicted worse OS (HR 2.39; p = 0.008). CDK4/6 inhibitor-based therapy shows meaningful activity in gBRCAm HR+/HER2- MBC; the numerically poorer outcomes observed in BRCA2 carriers are hypothesis-generating and warrant validation in larger cohorts.